Product Information
- N-((1-Methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl)acetyl)glycine
- 2-[[2-[1-Methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetic acid
Tolmetinglycinamide is a non-steroidal anti-inflammatory drug (NSAID) - a p-gp inhibitor. It has been shown to have a high activity index and to be stable at physiological pH. Tolmetinglycinamide also inhibits gsh-px activities and has been shown to have an antiinflammatory effect in mice. In addition, it has been shown to reduce the incidence of choroidal neovascularization in rats, as well as to inhibit the progression of cataracts in diabetic rats. These biological properties are correlated with its ability to suppress symptoms of inflammatory diseases such as pulmonary emphysema, rheumatoid arthritis, or osteoarthritis. Tolmetinglycinamide is metabolized by oxidation and hydrolysis by esterases or glucuronidases, which may lead to adverse effects such as gastrointestinal irritation or kidney toxicity.